Sign In
Buy IONS
$55.07
+0.580 (+1.06%)
At Close: Aug 04, 2026
Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript
04:52pm, Thursday, 01'st Aug 2024
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2024 Earnings Conference Call August 1, 2024 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief
Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:07am, Thursday, 01'st Aug 2024
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
09:20am, Thursday, 01'st Aug 2024
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.60 per share a year ago.
Ionis reports second quarter 2024 financial results
07:00am, Thursday, 01'st Aug 2024
WAINUA TM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U
Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PI
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Thursday, 25'th Jul 2024
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
10:56am, Tuesday, 23'rd Jul 2024
Data from an early-stage study shows that treatment with Ionis' (IONS) ION582 helps improve communication, cognition and motor function in patients with Angelman syndrome, a rare nerve disorder.
Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)
01:15pm, Monday, 22'nd Jul 2024
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) HALOS Study of ION582 in Angelman Syndrome Conference Call July 22, 2024 8:00 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relat
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
01:04pm, Monday, 22'nd Jul 2024
Ionis Pharmaceuticals Inc IONS released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS).
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
07:00am, Monday, 22'nd Jul 2024
ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
11:00am, Friday, 19'th Jul 2024
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
Ionis to hold second quarter 2024 financial results webcast
08:24am, Friday, 19'th Jul 2024
Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
07:00am, Thursday, 18'th Jul 2024
Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition CARLSBAD, Calif. , July 18, 2024 /PRNewswir
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
07:05am, Monday, 08'th Jul 2024
Webcast scheduled for Monday, July 22 at 8:00 a.m. Eastern Time CARLSBAD, Calif.
This cheap biotech offers investors a play on ALS if trial data continues to impress
12:34pm, Tuesday, 02'nd Jul 2024
NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
